A Prospective, Non-interventional Study to Evaluate the Efficacy and Safety of Iptacopan in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) in Routine Clinical Practice in the Russian Federation
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This is a prospective, non-interventional, multicenter study to evaluate the efficacy and safety of iptacopan in patients with PNH in real-world settings in Russia.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥18 years at the start of iptacopan therapy.
• The patient is undergoing treatment with iptacopan.
• The treating physician decided to prescribe iptacopan based on the Summary of Product Characteristics during routine clinical practice, regardless of study participation.
• Provision of written informed consent.
Locations
Other Locations
Russian Federation
Novartis Investigative Site
RECRUITING
Saint Petersburg
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2025-07-28
Estimated Completion Date: 2028-01-31
Participants
Target number of participants: 100
Treatments
iptacopan
Adults with PNH who started the iptacopan therapy
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals